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Liver cirrhosisAbstract Background: Chronic Hepatitis C virus (HCV) infection and liver cirrhosis may be asso-
ciated with atherosclerosis and coronary artery disease (CAD). There are two phases to atheroscle-
rosis, Subclinical and Clinical. Assessment of atherosclerosis may be started at its Subclinical phase
by the evaluation of Epicardial Fat Thickness (EpFT) and Carotid Intima Thickness (CIMT).
Aim of the study: The aim of the study was to evaluate Clinical and Subclinical atherosclerosis in
chronic HCV patients with and without liver cirrhosis by evaluating CIMT and EpFT and corre-
lating the results with Child-Pugh functional scoring of cirrhosis as well as with ultrasound and lab-
oratory parameters that define the severity of liver disease.
Patients and methods: This study involved 64 chronic HCV patients that were divided into two
groups: 24 patients without liver cirrhosis and 40 patients with liver cirrhosis in addition to 20 appar-
ently healthy volunteers serving as control. All of the 84 subjects were subjected to the following:
Clinical evaluation; Routine Laboratory Evaluation (CBC, Liver Function Tests, Renal Function
Tests, Serum electrolytes, Cholesterol, Triglycerides, HBs antigen and HCV antibody); ECG;
Abdominal ultrasound; Echocardiographic evaluation of segmental wall motion abnormalities
and EpFT and B-Mode Carotid ultrasonography for evaluation of CIMT.
Results: In the cirrhotic HCV group, the CIMT and EpFT were both significantly increased [Com-
pared to control group (p= 0.000), compared to the non-cirrhotic HCV group (p= 0.000)]. In the
non-cirrhotic HCV group, the CIMT and EpFT were both significantly increased compared to the
control group with a p-value of 0.003 for CIMT and 0.048 for EpFT. The CIMT and EpFT werey artery
thoracic
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http://dx.doi.org/10.1016/j.ehj.2016.10.004also positively correlated with each other (r= 0.456, p= 0.001). There was a statistically signifi-
cant increase in the EpFT and CIMT in Child class B patients compared to Child class A
(p= 0.007 for CIMT and p= 0.028 for EpFT) and in Child class C patients compared to Child
class B patients (p= 0.001 for CIMT and 0.005 for EpFT). CIMT and EpFT were correlated pos-
itively with AST (r= 0.385, p= 0.002 for CIMT, and r= 0.379, p= 0.003 for EpFT), Total
Bilirubin (r= 0.378, p= 0.003 for CIMT, and r= 0.384, p= 0.002 for EpFT), INR%
(r= 0.456, p= 0.001 for CIMT, and r= 0.384, p= 0.001 for EpFT), CRP (r= 0.378,
p= 0.003 for CIMT, and r= 0.386, p= 0.002 for EpFT), spleen span (r= 0.417, p= 0.001 for
CIMT, and r= 0.437, p= 0.001 for EpFT) and portal Vein Diameter (r= 0.372, p= 0.003 for
CIMT, and r= 0.379, p= 0.003 for EpFT). CIMT and EpFT were correlated negatively with
Albumin (r= 0.379, p= 0.003 for CIMT, and r= 0.370, p= 0.003 for EpFT), platelets count
(r= 0.382, p= 0.002 for CIMT, and r= 0.378, p= 0.003 for EpFT) and Liver Span
(r= 0.433, p= 0.001 for CIMT, and r= 0.424, p= 0.001 for EpFT).
Conclusion: EpFT and CIMT significantly increased in chronic hepatitis C virus patients especially
in those with cirrhosis and closely correlated with each other. Their thickness also correlated with
the Child-Pugh functional scoring of cirrhosis as well as with ultrasound and laboratory parameters
that define the severity of liver disease.
The echocardiographic assessment of EpFT and the carotid Doppler assessment of CIMT may pro-
vide appropriate and simple screening markers for subclinical atherosclerosis and cardiovascular
risk in chronic HCV patients with and without cirrhosis.
 2016 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atherosclerosis is one of leading causes of mortality and mor-
bidity throughout the world. It is a chronic, progressive,
inflammatory disease with a long asymptomatic course.1
Atherosclerosis passes through two phases, a Pre-clinical (Sub-
clinical) phase and a Clinical phase. The Subclinical phase
refers to the early stages of atherosclerotic disease and confers
an increased risk of cardiovascular disease which may eventu-
ally lead to coronary artery disease. A variety of imaging
modalities have been used to assess subclinical
atherosclerosis.1,2
Infectious agents including chronic hepatitis C virus (HCV)
infection have been associated with atherosclerosis and a
higher risk of coronary artery disease.3 Suggested mechanisms
include the promotion of HCV endocytosis4,5 by low-density
lipoprotein receptor and induction of oxidative stress by
HCV core protein leading to the oxidation of lipoprotein in
atherosclerotic plaques.6 It has also been associated with sys-
temic vasculitides7, increased concentration of soluble intercel-
lular adhesion molecules8 and the presence of anti-endothelial
antibodies.9
HCV patients are also at increased risk of developing hep-
atic steatosis.10,11 Patients with hepatic steatosis may have
underlying metabolic abnormalities including insulin resis-
tance as well as increased inflammatory markers that may con-
tribute to endothelial dysfunction.12–16 The presence of
steatosis may contribute to the development of other metabolic
diseases, such as hypertension and diabetes, all of which may
exacerbate CAD risk in individuals with HCV. Adinolfi et al.11
performed a study on HCV patients with and without hepatic
steatosis and found a significantly higher prevalence of carotid
atherosclerosis in HCV patients compared to age- and sex-
matched controls. In addition, even after matching for the
presence of steatosis, a significantly higher prevalence of caro-
tid atherosclerosis was seen in the HCV patients, supportingEK et al. Atherosclerosis in chronic hepthe notion that HCV may increase the risk of carotid
atherosclerosis independent of steatosis.11
It was believed that cirrhosis of the liver had a protective
role for CAD.17–19 These observations were motivated by a
theoretical protective role of some common features in cir-
rhotic patients like reduced circulating low-density lipopro-
teins and total cholesterol,20 decreased vascular resistance,
low blood pressure,21 and high levels of circulating estrogens.19
Now end-stage liver disease (ESLD) could be considered to be
a coronary artery risk equivalent, and it is therefore important
to appropriately risk-stratify patients even in the absence of
symptoms.22 It was found that the prevalence of coronary
artery disease (CAD) in liver transplanted (LT) candidates
can reach up to 26%.23 In turn, CAD is associated with
increased post-LT mortality and a greater incidence of new
cardiovascular morbidity.24
Epicardial fat thickness (EpFT), carotid intima media
thickness (CIMT), and aortic stiffness index have been used
to assess subclinical atherosclerosis.1,2
CIMT is a simple and inexpensive tool to assess the cumu-
lative effect of atherosclerotic risk factors and is recommended
by the American Heart Association for the noninvasive assess-
ment of cardiovascular risk.25–27 Some studies have reported
that HCV infected patients had higher CIMT compared to
healthy control subjects11,28 and the mean CIMT of HCV
infected patients was significantly greater than that of healthy
controls; this difference cannot be attributed to a difference in
age, gender, body mass index (BMI) or cadiometabolic risk
factors.29
Epicardial Fat Thickness (EpFT) may reflect the amount of
visceral fat, which is associated with insulin resistance, inflam-
mation and CAD.30 EpFT is a rich source of free fatty acids
and a number of bioactive molecules and inflammatory cyto-
kines.31–34 Some reports have suggested a crucial role of EpFT
in the development of CAD through changes in adipokine
expressions in EpFT, which promote pro-inflammatory char-
acteristics, thereby facilitating the progression of coronaryatitis C virus patients with and without liver cirrhosis, The Egypt Heart J (2016),
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echocardiography significantly correlates with CAD and is
considered a marker of severity of coronary lesions.36 EpFT
has been considered to be a possible cardiovascular risk indica-
tor.37,38 Assessment of EpFT by transthoracic echocardiogra-
phy (TTE) could be a simple and practical tool for
cardiovascular risk stratification in clinical practice.39,40
2. Aim of the study
The study aimed to evaluate clinical and subclinical atheroscle-
rosis in chronic hepatitis C virus patients with and without
liver cirrhosis by evaluating carotid EpFT and CIMT as well
as to correlate the degree of EpFT and CIMT with the
Child-Pugh functional scoring of cirrhosis and with the ultra-
sound and laboratory parameters that define the severity of
liver disease.
3. Patients and methods
3.1. Patients
3.1.1. Inclusion criteria
This study was carried out in 2014 and 2015 and included 64
patients with chronic hepatitis C virus from outpatient clinics
and outpatient services of Theodor Bilharz Research Institute
Hospital. These patients were divided into two groups accord-
ing to findings of transient ultrasound elastography fibro-
scan41–43 and abdominal ultrasound.
Group I: included 24 patients with chronic hepatitis C virus
without liver cirrhosis, fibro-scan was F0-F1 and liver ultra-
sound showed no apparent cirrhosis.
Group II: included 40 patients with chronic hepatitis C
virus with liver cirrhosis, fibro-scan was F4 and abdominal
ultrasound showed shrunken and irregular liver surface,
ascites and splenomegaly. They were classified according
to the Child-Pugh functional scoring of cirrhosis.
Group III: included 20 apparently healthy volunteers as
control group matched for age and sex and with normal
liver ultrasound, normal liver function tests and negative
hepatitis markers.
3.1.2. Exclusion criteria
Subjects with history of heart disease, diabetes mellitus, hyper-
tension (blood pressure >140/90 mmHg), smoking, hyperlipi-
demia, acute or chronic kidney disease, alcohol consumption,
pregnancy, liver masses, and anemia with hemoglobin less
10 g% were excluded from the study.
3.2. Methods
3.2.1. General methods
All patients in the study were subjected to the following:
– Thorough history taking and physical examination.
– Blood sampling for blood picture, liver function tests, renal
function tests, serum electrolytes, cholesterol, triglyceride,
HBs antigen and HCV antibody.Please cite this article in press as: Barakat A-AEK et al. Atherosclerosis in chronic hep
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findings suggestive of CAD.
– Abdominal ultrasound scanning was performed to all sub-
jects using a Toshiba Nemo 30 scanner equipped with a
3.5 MHz linear transducer by a member of the study team.
3.2.2. Transthoracic echocardiography
Echocardiography was performed using a Toshiba Nemo 30
scanner equipped with a 2.5 MHz linear transducer to detect
segmental wall motion abnormalities suggestive of CAD and
to measure epicardial fat thickness.
Epicardial fat thickness was identified as the echocardio-
graphically free space between the outer wall of the myocar-
dium and the visceral layer of the pericardium, and its
thickness was measured perpendicularly to the free wall of
the right ventricle at end-systole over 3 cardiac cycles. The
mean value of 3 cardiac cycles from each echocardiographic
view (including both parasternal long- and short-axis views)
was recorded as the EpFT.44 These measurements were com-
pleted by three blinded members of the study team and mea-
surements were averaged.
3.2.3. B mode carotid ultrasonography
High resolution B mode ultrasonography of both the common
carotid arteries was performed using an ultrasound machine
(Toshiba Memo 30 scanner) equipped with a 7.5 MHz high
resolution transducer. Patients were examined in the supine
position. The maximum CIMT was measured at the posterior
wall of the common carotid artery, 2 cm before the bifurca-
tion, as the distance between the first and second echogenic
lines of the anterior and posterior arterial walls. CIMT was
defined as a low-level echo gray band that does not project into
the arterial lumen45 and was measured during end diastole.
These measurements were completed by three blinded mem-
bers of the study team and measurements were averaged.
4. Ethics
All patients were provided by informed consent, and the ethi-
cal committee of the hospital approved this study which was
conducted in accordance with the Helsinki Declaration (1975).
5. Statistical analysis
Statistical analysis was performed using SPSS version 17. Data
were expressed as the mean ± standard deviation (SD) for
numerical variables. P 6 0.05 was considered to be statistically
significant and P 6 0.01 was considered to be highly statisti-
cally significant. The univariate correlations of the carotid
intima-media thickness and epicardial fat thickness with other
parameters were also done.
6. Results
The demographic data of the patient groups and the control
group revealed mean ages of 41.3 ± 9.95 years for the non-
cirrhotic hepatitis C group, 42.5 ± 8.75 years for the cirrhotic
group and 43.2 ± 7.85 years for the control group. In the non-
cirrhotic hepatitis C group 16 patients (66.7%) were males andatitis C virus patients with and without liver cirrhosis, The Egypt Heart J (2016),
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patients (60%) were males and 16 patients (40%) were females
and in the control group, there were 13 males (65%) and 7
females (35%). There were no significant differences between
the patient groups and the control group regarding age and
gender (Table 1).
Hepatitis C patients with cirrhosis had a statistically signif-
icant decrease in systolic blood pressure together with a statis-
tically significant increase in heart rate compared to the
controls. Also, they had a statistically significant increase in
their heart rate compared to hepatitis C patients without cir-
rhosis (Table 1).
The electrocardiographic findings showed inverted T and
depressed ST segment in 2 patients (8.33%) having hepatitis
C without cirrhosis, in 5 patients (12.5%) having hepatitis C
with cirrhosis and in no subjects of the control group. These
results were neither statistically significant between the
patient groups and control nor between both patient groups
(Table 1).
Regarding the echocardiographic findings, segmental wall
motion abnormalities at rest were found in 1 patient (4.17%)
having hepatitis C without cirrhosis, in 4 patients (10%) hav-
ing hepatitis C patients with cirrhosis and in no subjects of the
control group. These results were neither statistically signifi-
cant between the patient groups and control nor between both
patient groups (Table 1).
Regarding the laboratory data, hepatitis C patients with
cirrhosis had statistically significant decrease in serum sodium,
albumin and platelets count together with statistically signifi-
cant increase in serum potassium, total bilirubin, INR and
CRP compared to the control group and to the non-cirrhotic
hepatitis C patients group. Also, hepatitis C patients with cir-
rhosis had statistically significant increase in ALT and AST
compared to control group. Non-cirrhotic hepatitis C patients
had statistically significant decrease in serum sodium, albumin
and platelets count in addition to a statistically significant
increase in serum AST, ALT, total bilirubin, INR and CRP
compared to the control group (Table 2).
All patients had hepatitis C positive antibodies. All the
non-cirrhotic hepatitis C patients had F0-F1 fibro-scan withTable 1 Demographic data, ECG and echocardiographic findings
Hepatitis C without cirrhosis
N= 24
Hepati
N= 4
Age 41.3 ± 9.95 42.5 ±
Years
Gender
Male 16 (66.7%) 24 (60
Female 8 (33.3%) 16 (40
Systolic BP, mmHg 116.8 ± 11.2 114.5 ±
Diastolic 68.8 ± 12.5 67.0 ±
BP, mmHg
Pulse beat/min 76.3 ± 7.2 81.3 ±
ECG findings suggestive of CAD 2 (8.33%) 5 (12.5
Echo findings suggestive of CAD 1 (4.17%) 4 (10%
P1 value, between groups 1 and 3; P2 value, between groups 2 and 3; P
P 6 0.01, highly statistically significant. ECG: electrocardiogram; CAD:
Please cite this article in press as: Barakat A-AEK et al. Atherosclerosis in chronic hep
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(100%). Regarding the cirrhotic group, 32 patients (80%)
had cirrhosis, ascites and splenomegaly by abdominal ultra-
sound while all the patients had F4 fibro-scan (Table 3).
Regarding the abdominal ultrasonographic findings of the
cirrhotic group, there was a statistically significant decrease
in the liver span together with statistically significant increase
in the spleen span and portal vein diameter compared to both
the control group and the non-cirrhotic hepatitis C group. The
non-cirrhotic hepatitis C patients also showed a statistically
significant increase in the spleen span and the portal vein diam-
eter compared to the control group. Ascites was present in 2
patients of the non-cirrhotic group (8.33%) compared to 34
patients of the cirrhotic group (85%) and it was not present
in any of the subjects of the control group (Table 3). The 2
patients having ascites in the non-cirrhotic group were females
with ruptured ovarian cysts.
Carotid intima-media thickness and epicardial fat thickness
were significantly increased in the cirrhotic hepatitis C group
compared to both the control group and the non-cirrhotic
group. Also, the non-cirrhotic hepatitis C group showed statis-
tically significant increase in the carotid intima-media thick-
ness and epicardial fat thickness compared to control group
(Table 4).
There was a statistically significant increase in CIMT in
Child class B patients compared to Child class A patients
and in Child class C patients compared to Child class B
patients Table 5.
There was a statistically significant increase in EpFT in
Child class B patients compared to Child class A patients
and in Child class C patients compared to Child class B
patients Table 6.
CIMT was positively correlated with AST, total bilirubin,
INR%, CRP, spleen span, portal vein diameter and EpFT
and negatively correlated with albumin, platelets count and
liver span in HCV infected patients (Table 7).
EpFT was positively correlated with AST, total bilirubin,
INR%, CRP, spleen span, and portal vein diameter; and
CIMT negatively correlated with albumin, platelets count
and liver span in HCV infected patients (Table 8).suggestive of CAD of the studied groups.
tis C with cirrhosis
0
Control
group
N= 20
P1 value P2 value P3 value
8.75 43.2 ± 7.85 0.492 0.764 0.617
%) 13 (65%) 0.569 0.703 0.904
%) 7 (35%) 0.904 0.704 0.596
8.6 120.3 ± 8.1 0.250 0.015 0.359
8.4 70.7 ± 8.2 0.563 0.111 0.493
7.8 75.3 ± 6.8 0.641 0.005 0.013
%) 0 (0%) 0.187 0.099 0.603
) 0 (0%) 0.358 0.144 0.399
3 value, between groups 1 and 2. P 6 0.05, statistically significant;
coronary artery disease; Echo: echocardiography.
atitis C virus patients with and without liver cirrhosis, The Egypt Heart J (2016),
Table 2 Laboratory data of the studied groups.
Hepatitis C without cirrhosis
N= 24
Hepatitis C with cirrhosis
N= 40
Control group
N= 20
P1 value P2 value P3 value
Na, mEq/L 136.85 ± 5.44 130.16 ± 6.74 141.64 ± 2.04 0.001 0.000 0.000
K, mEq/L 4.05 ± 0.24 4.78 ± 0.56 4.14 ± 0.22 0.206 0.000 0.000
Creat, mg/dL 0.95 ± 0.3 1.0 ± 0.2 0.92 ± 0.2 0.705 0.150 0.427
ALT, U/L 61.78 ± 33.85 51.65 ± 20.29 23.85 ± 2.06 0.000 0.000 0.139
AST, U/L 53.8 ± 16.89 74.96 ± 57.76 23.65 ± 4.04 0.000 0.000 0.086
T bil., mg/dL 1.56 ± 0.36 3.32 ± 3.79 0.54 ± 0.11 0.000 0.000 0.027
Albumin, g/dL 3.51 ± 0.48 2.47 ± 0.49 4.21 ± 0.7 0.000 0.000 0.000
Platelets count 109/L 164.2 ± 32.7 62.6 ± 57.3 224.7 ± 58.7 0.000 0.000 0.000
INR% 1.13 ± 0.24 1.69 ± 0.5 1.01 ± 0.13 0.000 0.012 0.000
LDL, mg/dL 106.4 ± 18.5 102.6 ± 17.5 109.6 ± 16.4 0.551 0.071 0.331
HDL, mg/dL 44.2 ± 15.4 43.4 ± 14.6 46.2 ± 11.6 0.635 0.458 0.836
Tl Choles., mg/dL 151.2 ± 34.3 148.2 ± 31.3 153.2 ± 41.3 0.603 0.862 0.722
TG, mg/dL 112.3 ± 46.5 110.6 ± 40.5 121.9 ± 27.7 0.422 0.267 0.878
CRP, mg/L 5.6 ± 2.1 7.2 ± 2.5 2.3 ± 0.4 0.000 0.000 0.011
P1 value, between groups 1 and 3; P2 value, between groups 2 and 3; P3 value, between groups 1 and 2.
P 6 0.05, statistically significant; P 6 0.01, highly statistically significant.
Na: serum sodium; K: serum potassium; Creat: creatinine; ALT: alanine aminotransferase; AST: aspartate aminotransferase; T bil.: Total
bilirubin; INR: international normalized ratio; LDL: low density lipoprotein; HDL: high density lipoprotein; Tl Choles: total cholesterol; TG:
Triglyceride; CRP: C reactive protein.
Table 3 Fibro-scan and abdominal ultrasound data of the studied groups.
Hepatitis C without cirrhosis
N= 24
Hepatitis C with cirrhosis
N= 40
Control group
N= 20
P1 value P2 value P3 value
Fibro-scan F0-F1 (24) (100%) F4 (40) (100%) ve
Coarse liver ve +ve (32) (80%) ve 0.000 0.000
Liver span, cm 14.3 ± 2.7 12.4 ± 3.1 14.7 ± 1.1 0.539 0.002 0.016
Ascites +ve (2) (8.33%) +ve (34) (85%) ve 0.187 0.000 0.000
Spleen span, cm 14.2 ± 2.4 16.3 ± 3.7 8.2 ± 2.3 0.000 0.000 0.016
PV diameter, mm 8.5 ± 2.6 13.7 ± 3.4 7.1 ± 1.2 0.032 0.000 0.000
P1 value, between groups 1 and 3; P2 value, between groups 2 and 3; P3 value, between groups 1 and 2.
P 6 0.05, statistically significant; P 6 0.01, highly statistically significant.
Table 4 Carotid intima-media thickness and epicardial fat thickness of the studied groups.
Hepatitis C without cirrhosis
N= 24
Hepatitis C with cirrhosis
N= 40
Control group
N= 20
P1 value P2 value P3 value
CIMT, mm 8.2 ± 1.4 11.9 ± 1.8 6.2 ± 2.7 0.003 0.000 0.000
EpFT, mm 4.4 ± 1.8 6.7 ± 2.1 3.2 ± 1.3 0.048 0.000 0.000
P1 value, between groups 1 and 3; P2 value, between groups 2 and 3; P3 value, between groups 1 and 2.
P 6 0.05, statistically significant; P 6 0.01, highly statistically significant.
CIMT: carotid intima-media thickness and EpFT: epicardial fat thickness
Atherosclerosis in chronic hepatitis C virus patients 57. DiscussionAtherosclerosis is a chronic, progressive and inflammatory dis-
ease with a long asymptomatic prelude.1 Atherosclerosis has
two phases: preclinical (subclinical) and clinical. Subclinical
atherosclerosis refers to the early stages of the atherosclerotic
disease, and may lead to coronary artery disease. A variety
of imaging modalities have been used to assess subclinical
atherosclerosis.1,2Please cite this article in press as: Barakat A-AEK et al. Atherosclerosis in chronic hep
http://dx.doi.org/10.1016/j.ehj.2016.10.004O’Leary et al. in their study concluded that CIMT is a sim-
ple and inexpensive tool to assess the cumulative effect of
atherosclerotic risk factors and is an independent predictor
of future cardiovascular risk.25 The ultrasound-based measure-
ment of CIMT has become a standard for assessing arterioscle-
rosis and is recommended by the American Heart Association
for the noninvasive assessment of cardiovascular risk.26,27
Ahn et al. found that EpFT is strongly related to the devel-
opment of coronary artery disease.30 Also Shemirani et al.
found that increased EpFT is correlated with the severity ofatitis C virus patients with and without liver cirrhosis, The Egypt Heart J (2016),
Table 5 Carotid intima-media thickness in patients with
cirrhosis as related to their Child-Pugh classification.
Group (n) CIMT p-value
Controls (20) 6.2 ± 2.7
HCV with Cirrhosis (40) 11.9 ± 1.8 0.000
Child class A (10) 9.2 ± 1.7
Child class B (14) 10.9 ± 1.1 0.007
Child class C (16) 12.5 ± 1.2 0.001
P 6 0.05, statistically significant; P 6 0.01, highly statistically
significant.
HCV: hepatitis C virus and CIMT: carotid intima-media thickness.
p< 0.000: cirrhosis group (total) compared to control group;
p= 0.007: child class B group compared to child class A group;
p= 0.001: child class C group compared to child class B group.
Table 6 Epicardial fat thickness in patients with cirrhosis as
related to their Child-Pugh classification.
Group (n) EpFT p-value
Controls (20) 3.2 ± 1.3
HCV with Cirrhosis (40) 6.7 ± 2.1 0.000
Child class A (10) 4.6 ± 1.5
Child class B (14) 5.9 ± 1.2 0.028
Child class C (16) 7.3 ± 1.3 0.005
P 6 0.05, statistically significant; P 6 0.01, highly statistically
significant.
HCV: hepatitis C virus and EpFT: epicardial fat thickness.
p< 0.000: cirrhosis group (total) compared to control group;
p= 0.028: child class B group compared to child class A group;
p= 0.005: child class C group compared to child class B group.
Table 7 Correlation of different variables in HCV infected
patients with CIMT.
Parameter r-value p-value
AST, U/L 0.385 0.002
T bil., mg/dL 0.378 0.003
Albumin, g/dL -0.379 0.003
Platelets count 109/L -0.382 0.002
INR% 0.456 0.001
CRP, mg/L 0.378 0.003
Liver span, cm -0.433 0.001
Spleen span, cm 0.417 0.001
PV diameter, mm 0.372 0.003
EpFT, mm 0.465 0.001
P 6 0.05, statistically significant; P 6 0.01, highly statistically
significant.
AST: aspartate aminotransferase; T bil.: Total bilirubin; INR:
international normalized ratio; CRP: C reactive protein; PV: portal
vain; EpFT: epicardial fat thickness.
Table 8 Correlation of different variables in HCV infected
patients with EpFT.
Parameter r-value p-value
AST, U/L 0.379 0.003
T bil., mg/dL 0.384 0.002
Albumin, g/dL 0.370 0.003
Platelets count 109/L 0.378 0.003
INR% 0.430 0.001
CRP, mg/L 0.386 0.002
Liver span, cm 0.424 0.001
Spleen span, cm 0.437 0.001
PV diameter, mm 0.379 0.003
CIMT, mm 0.465 0.001
P 6 0.05, statistically significant; P 6 0.01, highly statistically
significant.
AST: aspartate aminotransferase; T bil.: Total bilirubin; INR:
international normalized ratio; CRP: C reactive protein; PV: portal
vain; CIMT: carotid intima-media thickness.
6 A. A. E.-K. Barakat et al.coronary artery stenosis.36 Cetin et al. found that EpFT of
6.3 mm was determined as a high risk value for subclinical
atherosclerosis with a 72.5% sensitivity and 71.7% speci-
ficity.46 Many other previous studies have reported thatPlease cite this article in press as: Barakat A-AEK et al. Atherosclerosis in chronic hep
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drome.47–50
In our study, there was significant correlation between
EpFT measured by carotid ultrasound and CIMT measured
by echocardiography. Iacobellis et al. were the first authors
to demonstrate a significant correlation between epicardial
fat and CIMT.51 Abaci et al. also demonstrated a significant
correlation between epicardial fat and CIMT.52 Rego et al.
examined 300 asymptomatic subjects and found that epicardial
fat had a significant association with CIMT, coronary artery
calcification, increased ApoB/ApoA1 ratio and cardiovascular
risk according to the Framingham score.53 The prevalence of
carotid plaque was significantly greater in those with EpFT
thicknessP 5 mm who had low Framingham risk scores com-
pared with those with EpFT thickness < 5 mm.54
In the current study, in spite of excluding patients having
history of ischemic heart disease, the electrocardiogram
showed inverted T wave and depressed ST segment in 2
(8.33%) patients having non-cirrhotic hepatitis C and in 5
patients (12.5%) having cirrhotic hepatitis C. These results
were neither statistically significant between the patient groups
and control nor between both patient groups. Echocardiogra-
phy showed wall motion abnormalities at rest in 1 patient
(4.17%) having non-cirrhotic hepatitis C and in 4 (10%)
patients having cirrhotic hepatitis C. These results were not
statistically significant between patient groups and control or
between both patient groups. Our study showed statistically
significant increase of CIMT and EpFT in the hepatitis C cir-
rhotic group compared to the control group and to the hepati-
tis C non-cirrhotic group. Also, hepatitis C non-cirrhotic
patients had statistically significant increase in CIMT and
EpFT compared to the control group. These findings suggest
increased prevalence of subclinical atherosclerosis in hepatitis
C patients especially in the presence of cirrhosis.
In agreement with our findings, Butt et al. have found that
HCV infection was associated with a higher risk of atheroscle-
rosis and coronary artery disease after adjustment of tradi-
tional risk factors.3 The study by Ampuero and Romero-
Go´mez revealed a strong link between HCV infection and
the atherogenic process, showing a higher risk of coronaryatitis C virus patients with and without liver cirrhosis, The Egypt Heart J (2016),
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and, ultimately, CVD-related mortality.55 Lin et al. reported
that HCV-infected subjects had 1.76-fold increased risk of an
ischemic electrocardiogram when compared with HCV non-
infected subjects.56 Zakaria et al. found that mean CIMT of
HCV infected Egyptians of a low cardiovascular risk was sig-
nificantly greater than that of healthy controls.29 Although the
results of some studies suggest that hepatitis C infection is an
independent risk factor for carotid atherosclerosis,57,58 these
findings have not been confirmed by others who have shown
that chronic viral hepatitis may protect from atherosclerosis
in the carotid arteries.59 In another report, no independent
association could be found between serological markers for
hepatitis C virus infection and cardiovascular morbidity or
atherosclerosis in the carotid arteries.60
Assessing cirrhotic candidates for LT has revealed a high
prevalence of asymptomatic CAD in these patients. Sixty-five
LT candidates without known CAD underwent multidetector
computed tomography coronary angiography: 58% had mild
CAD and 34% had moderate to severe CAD.61 Other studies
have revealed a significant burden of unrecognized, asymp-
tomatic CAD.62,22 Carey et al.63 reported that 13.3% of liver
transplanted patients with moderate or severe coronary steno-
sis were asymptomatic, presumably due to the masking effect
of poor functional status.
Our study revealed that CRP was significantly increased in
hepatitis C patients with cirrhosis compared to the control
group and hepatitis C patients without cirrhosis. Our study
agrees with many studies which concluded that the majority
of endothelial biomarkers were elevated in the chronic HCV
patients. Although varied, the biomarker pattern points to
an increased risk of cardiovascular mortality in the chronic
HCV patients: CRP, sVCAM-1, sICAM-1, and s-E-selectin,
were all elevated in these patients.64–66 Shimada et al. found
that elevated serum level of CRP is an independent predictor
of cardiovascular events in patients with CAD.67
In our study, there were positive correlations between
CIMT and AST, total bilirubin, INR%, CRP, spleen span,
portal vein diameter and EpFT in addition to negative corre-
lations between CIMT and albumin, platelets count and liver
span in all HCV infected patients. There were also positive cor-
relations between EpFT and AST, total bilirubin, INR%,
CRP, spleen span, portal vein diameter and CIMT in addition
to negative correlations between EpFT and albumin, platelets
count and liver span in all HCV infected patients. These find-
ings in addition to the statistically significant increase of EpFT
and CIMT in correlation with the Child-Pugh functional scor-
ing of cirrhosis indicate that the subclinical atherosclerosis
detected in our patients with hepatitis C is correlated with
the functional scoring of cirrhosis and the severity of liver
disease.
In agreement with our findings, Petta and his colleagues
have found that severe hepatic fibrosis is associated with a
higher risk of carotid atherosclerosis in chronic hepatitis C
patients.68 In another study carried out on fatty liver patients,
Petta et al. found that higher epicardial fat thickness is associ-
ated with the severity of liver fibrosis; in addition to that they
concluded that the morphological and functional cardiac alter-
ations are more pronounced in accordance with the severity of
fibrosis.69 Dogan and his colleagues found that the Framing-
ham risk score (FRS) which provides an estimate of coronaryPlease cite this article in press as: Barakat A-AEK et al. Atherosclerosis in chronic hep
http://dx.doi.org/10.1016/j.ehj.2016.10.004heart disease (CHD) risk is associated with the noninvasive
scoring indexes like fibrosis scan and they also found that
assessment of liver fibrosis in patients with fatty liver may be
useful for the risk stratification of CHD in the absence of liver
biopsy in clinical practice.70
8. The novelty of the study
To our knowledge the present study is unique in assessing
EpFT in post hepatitis C liver cirrhosis and in correlating
the degree of EpFT with Child-Pugh functional scoring of cir-
rhosis and with ultrasound and laboratory parameters that
define severity of liver disease. Previous studies have used
CIMT (not EpFT) for screening of atherosclerosis in hepatitis
C patients while EpFT have been used only in assessment of
atherosclerosis in fatty liver disease patients.
9. Limitation
For single-center study with small sample size, we suggest that
multicenter approaches may be necessary to attain larger sam-
ple sizes.
10. Conclusions
Our study revealed increased EpFT and CIMT in chronic hep-
atitis C virus patients especially in those with cirrhosis, and the
degree of EpFT and CIMT was shown to be correlated with
the Child-Pugh functional scoring of cirrhosis and with the
ultrasound and laboratory parameters that define severity of
liver disease. Our study also showed close correlation between
EpFT and CIMT in these patients.
The echocardiographic assessment of EpFT and the carotid
Doppler assessment of CIMT may provide appropriate and
simple screening markers for subclinical atherosclerosis and
cardiovascular risk in patients with chronic hepatitis C virus
with and without cirrhosis. Patients undergoing LT would
likely benefit from echocardiographic assessment of EpFT
and carotid Doppler for evaluation of CIMT in addition to
stress testing to help identify those patients who are at high
or low risk for cardiac outcomes in the LT.Conflict of interest
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